Reuters logo
BRIEF-Bayer applies for further marketing authorisation for regorafenib
November 7, 2016 / 7:37 AM / a year ago

BRIEF-Bayer applies for further marketing authorisation for regorafenib

Nov 7 (Reuters) - Bayer Ag

* Bayer says regorafenib from bayer submitted to health authorities seeking approval in second-line treatment of liver cancer

* Bayer says applications to extend the marketing authorization for its oral multi-kinase inhibitor regorafenib in the U.S., Japan and Europe Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below